Agreement between potential drug interactions identified by an electronic tool and clinical judgment: INTERCheck® versus physicians

S. Antoniazzi1,2, M.T. Chiarelli3, F. Venturini3, A. Nobili4, L. Pasina4, C. Casiraghi5, P. Santalucia1, M. Marcucci6, S. Damanti6, G. Periti7, M. Porzio7, R. Rossio3, F. Peyvandi8, S. Fargion7, D. Mari6, V. Monzani3, P.M. Mannucci1

1Scientific Direction, IRCCS Ca’ Granda Maggiore Hospital Policlinico Foundation Milano, Italy
2Unit of Clinical Pharmacology, Dept. of Biomedical and Clinical Sciences, University Hospital ‘Luigi Sacco’, University of Milan, Milano, Italy
3Pharmacy Unit, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milano, Italy
4Laboratory for Quality Assessment of Geriatric Therapies and Services, IRCCS Istituto di Ricerche Farmacologiche Mario Negri, Milano, Italy
5Emergency Medicine Dept., IRCCS Foundation Maggiore Hospital Policlinico, Milano, Italy
6Geriatric Unit, Dept. of Clinical Sciences and Community Health, University of Milano, Ca’ Granda Foundation, Maggiore Policlinico Hospital, Milano, Italy
7Internal Medicine and Metabolic Diseases, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milano, Italy
8Dept. of Pathophysiology and Transplantation, IRCCS Ca’ Granda Maggiore Policlinico Hospital Foundation, Milano, Italy

Background
The software INTERCheck® provides physicians with the potential drug-drug interactions (pDDIs) of a patient therapy, classifying them based on clinical relevance from the literature, as A(minor), B(moderate), C(major), D(contraindicated).
Aim: to assess the concordance between the pDDIs clinical relevance as classified by the electronic tool INTERCheck® and physician’s personal judgement; to explore the nature of drug-drug interaction for the more serious cases (e.g. C/D classes).

Materials and Methods
This retrospective study, conducted in 4 wards between April-October 2014, identified pDDIs from medical records of elderly inpatients ≥65years, taking ≥5drugs, by using INTERCheck®. Clinical relevance as classified by INTERCheck® was then compared with physician judgement through a structured interview consisting of four questions: is the actual pDDI known? is it clinically relevant?, if yes, why?, would knowledge of the pDDI at prescription time have changed your prescribing approach? Concordance between INTERCheck® and physician judgement was defined as: classification of ‘clinically relevant=yes’ by physician and class C-D by INTERCheck®; classification of ‘clinically relevant=no’ by physician and class A-B by INTERCheck®. Moreover, we analysed the drug classes according to Anatomical Therapeutic Chemical (ATC) Classification System for each drug involved in C and D pDDIs by INTERCheck®.

Results
Medical records of 60 inpatients were analyzed: 1658 drugs were prescribed, 448 unduplicated pDDIs were detected by INTERCheck® and subsequently evaluated by physicians. Of those, 227(51%) were unknown to the physician and 230(51%) were classified by them as clinically relevant: 154(67%) for the potential clinical impact, 54(24%) for patient complexity/co-morbidity, 17(7%) for other reasons. According to INTERCheck®, pDDIs were classified as: 12(3%) A; 275(61%) B; 108(24%) C and 53(12%) D. In accordance to the ATC classification system, we retrieved that the drug classes involved in pDDIs of C and D classes were as follows: Cardiovascular system 33%(107/322), Nervous system 24%(77/322), Blood and blood forming organs 12%(40/322), Respiratory system 10%(33/322), Antiinfectives for systemic use 9%(30/322), Alimentary tract and metabolism 6%(18/322), Musculo-skeletal system 2%(7/322), while Systemic hormonal preparations, Various, Antineoplastic and immunomodulating agents, Sensory organs were retrieved with a rate of 1%. The more detected pDDIs were: clopidogrel-rabeprazole, acetylsalicylic acid-nadroparin, amiodarone-salbutamol and bisoprolol-salbutamol. Excluding for clopidogrel-rabeprazole interacting with a pharmacokinetic mechanisms, the others three pDDIs were associated to pharmacodynamic effects.
Concordance between physician judgment and INTERCheck® was: 17%(2/12) for A, 39%(108/275) for B, 75%(81/108) for C, 74%(39/53) for D. According to the physicians knowledge of the pDDI at the time of prescription would resulted in therapy change in 23%(52/227) of cases.

Conclusions
An increasing concordance between INTERCheck® and physician’s judgement was found throughout the INTERCheck® classes. This finding will be taken into account to improve INTERCheck® action upon situations where a lower concordance was found.